Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02688309 · ClinicalTrials.gov registry record
Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases
A clinical trial, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- 44
- Enrollment target
NCT02688309: Clinical Trial study, sponsored by Johns Hopkins University.
NCT02688309 is a clinical trial that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02688309 was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- 44 participants
- Enrollment target
Study Summary
This study will examine potential factors in the aqueous humor that may contribute to the development or progression of macular edema or fibrosis (due to any underlying disease) in patients suffering from these conditions.
Interventions
- PROCEDURE Surgery
- DRUG Ozurdex
- PROCEDURE Anterior Chamber (AC) Tap
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2015-01-13 |
| Est. Completion | 2021-10-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02688309
The ClinicalTrials.gov registry entry for NCT02688309 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Surgery is the first listed.
NCT02688309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02688309 about?
NCT02688309 is a clinical study titled "Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases". This study will examine potential factors in the aqueous humor that may contribute to the development or progression of macular edema or fibrosis (due to any underlying disease) in patients suffering from these conditions.
What is the current status of trial NCT02688309?
This trial is currently terminated. The enrollment target is 44 participants. The study started on 2015-01-13. Estimated completion is 2021-10-28.
What interventions are being tested in trial NCT02688309?
The interventions under investigation include: Surgery (PROCEDURE), Ozurdex (DRUG), Anterior Chamber (AC) Tap (PROCEDURE).
Who is sponsoring clinical trial NCT02688309?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.